Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
U.S. Biomedical Advanced Research and Development Authority
Headquarters: Washington, DC, United States of America
Website: https://www.phe.gov/about/b...
Year Founded: 2006
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 13, 2024
Product Development
Vir evolves from antiviral one-stop shop to protein engineering play
Shedding non-protein platforms and bringing in masked bispecifics for cancer, the company’s pivot highlights the challenges of its founding thesis.
BioCentury | Aug 19, 2022
Deals
Aug. 18 Quick Takes: Early end to Bayer-Exscientia discovery deal
Plus FDA lifts Curis’ emavusertib hold and updates from Unity, Astellas, Lundbeck, Bavarian Nordic and more
BioCentury | Jun 11, 2022
Regulation
June 10 Quick Takes: Everest wins first China approval
Plus BARDA buys additional monkeypox and smallpox vaccine from Bavarian Nordic, and updates from Fulcrum, ADC, GSK and more
BioCentury | May 16, 2022
Deals
May 16 Quick Takes: Agios again narrows focus
Plus Shionogi-F2G, Chimerix, Travere, Valneva and more
BioCentury | Mar 26, 2022
Product Development
Replenishing CEPI
The Coalition for Epidemic Preparedness Innovations is gearing up to take the fight beyond COVID-19
BioCentury | Oct 6, 2021
Finance
Oct. 5 Quick Takes: Nextech leads $78M round for Exo
Plus updates from Zai, Vedanta, Taysha, IpiNovyx
BioCentury | Aug 4, 2021
Management Tracks
Qian joins LianBio as general manager of China
Hoffman out as Zymergen CEO, plus updates from Scholar Rock, Ironwood, Keros, Madrigal and more
BioCentury | Jun 17, 2021
Finance
Biden administration commits more than $3B to COVID-19 antiviral development, pandemic preparedness
The Biden administration is allocating more than $3 billion from American Rescue Plan funding towards its Antiviral Program for Pandemics, a collaboration between federal health agencies to support
BioCentury | Mar 20, 2021
Politics, Policy & Law
Becerra’s confirmation, O’Connell nomination spotlight FDA commissioner choice
Woodcock still in play to head FDA
BioCentury | Mar 11, 2021
Deals
March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis
Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage
Items per page:
1 - 10 of 40